$0.24 -0.00 (-0.04%)
Intensity Therapeutics, Inc. Common stock (INTS)
Intensity Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for solid tumors. The company aims to harness the body’s immune response to target and destroy cancer cells through its proprietary immunotherapy platforms. Based in the United States, Intensity Therapeutics is involved in research and development efforts to advance novel therapies for cancer patients.
Company News
Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Intensity Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference, where CEO Lewis H. Bender will discuss their lead investigational product INT230-6, a novel intratumoral cancer therapy designed to kill tumors and enhance immune system recognition.